Back to Browse Journals » ImmunoTargets and Therapy » Volume 1

T-cell activation is enhanced by targeting IL-10 cytokine production in toll-like receptor- stimulated macrophages

Authors Walk RM, Elliot ST, Blanco FC, Snyder JA, Jacobi AM, Rose SD, Behlke MA, Salem AK, Vukmanovic S, Sandler AD

Published Date November 2012 Volume 2012:1 Pages 13—23

DOI http://dx.doi.org/10.2147/ITT.S32615

Received 8 August 2012, Accepted 2 October 2012, Published 23 November 2012

Ryan M Walk,1,2 Steven T Elliott,2 Felix C Blanco,2 Jason A Snyder,2 Ashley M Jacobi,3 Scott D Rose,3 Mark A Behlke,3 Aliasger K Salem,4 Stanislav Vukmanovic,2 Anthony D Sandler2

1Department of Surgery, Walter Reed Army Medical Center, Washington, DC, USA; 2Sheikh Zayed Institute for Pediatric Surgical Innovation, Children's National Medical Center, Washington, DC, USA; 3Integrated DNA Technologies, Coralville, IA, USA; 4Division of Pharmaceutics, University of Iowa, Iowa City, IA, USA

Abstract: Toll-like receptor (TLR) agonists represent potentially useful cancer vaccine adjuvants in their ability to stimulate antigen-presenting cells (APCs) and subsequently amplify the cytotoxic T-cell response. The purpose of this study was to characterize APC responses to TLR activation and to determine the subsequent effect on lymphocyte activation. We exposed murine primary bone marrow-derived macrophages to increasing concentrations of agonists to TLRs 2, 3, 4, and 9. This resulted in a dose-dependent increase in production of not only tumor necrosis factor–alpha (TNF-α), a surrogate marker of the proinflammatory response, but also interleukin 10 (IL-10), a well-described inhibitory cytokine. Importantly, IL-10 secretion was not induced by low concentrations of TLR agonists that readily produced TNF-α. We subsequently stimulated lymphocytes with anti-CD3 antibody in the presence of media from macrophages activated with higher doses of TLR agonists and observed suppression of interferon gamma release. Use of both IL-10 knockout macrophages and IL-10 small-interfering RNA (siRNA) ablated this suppressive effect. Finally, IL-10 siRNA was successfully used to suppress CpG-induced IL-10 production in vivo. We conclude that TLR-mediated APC stimulation can induce a paradoxical inhibitory effect on T-cell activation mediated by IL-10.

Keywords: toll-like receptors, innate immunity, IL-10

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Update on the challenges and recent advances in cancer immunotherapy

Baronzio G, Parmar G, Shubina IZH, Cassutti V, Giuli S, Ballerini M, Kiselevsky M

ImmunoTargets and Therapy 2013, 2:39-49

Published Date: 17 June 2013

Update on immunopathogenesis and immunotherapy in multiple sclerosis

Selter RC, Hemmer B

ImmunoTargets and Therapy 2013, 2:21-30

Published Date: 26 April 2013

Gender difference in response predictors after 1-year exenatide therapy twice daily in type 2 diabetic patients: a real world experience

Anichini R, Cosimi S, Di Carlo A, Orsini P, De Bellis A, Seghieri G, Franconi F, Baccetti F

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2013, 6:123-129

Published Date: 8 April 2013

Preparation, characterization and application of star-shaped PCL/PEG micelles for the delivery of doxorubicin in the treatment of colon cancer

Gao X, Wang BL, Wei XW, Rao W, Ai F, Zhao F, Men K, Yang BW, Liu XY, Huang MJ, Gou ML, Qian ZY, Huang N, Wei YQ

International Journal of Nanomedicine 2013, 8:971-982

Published Date: 8 March 2013

Methacrylic-based nanogels for the pH-sensitive delivery of 5-Fluorouracil in the colon

Ashwanikumar N, Kumar NA, Nair SA, Kumar GS

International Journal of Nanomedicine 2012, 7:5769-5779

Published Date: 15 November 2012

Preparation of Fe3O4 magnetic nanoparticles coated with gallic acid for drug delivery

Dorniani D, Bin Hussein MZ, Kura AU, Fakurazi S, Shaari AH, Ahmad Z

International Journal of Nanomedicine 2012, 7:5745-5756

Published Date: 12 November 2012

Targeting myeloid-derived suppressor cells augments antitumor activity against lung cancer

Srivastava MK, Zhu L, Harris-White M, Huang M, St John M, Lee JM, Salgia R, Cameron RB, Strieter R, Dubinett S, Sharma S

ImmunoTargets and Therapy 2012, 1:7-12

Published Date: 12 October 2012

Cancer as an immune-mediated disease

Shurin MR

ImmunoTargets and Therapy 2012, 1:1-6

Published Date: 14 June 2012

Biologic targeting in the treatment of inflammatory bowel diseases

Matteo Bosani, Sandro Ardizzone, Gabriele Bianchi Porro

Biologics: Targets and Therapy 2009, 3:77-97

Published Date: 9 February 2009

Structure-based design of anticancer prodrug PABA/NO

Xinhua Ji, Ajai Pal, Ravi Kalathur, Xun Hu, Yijun Gu, et al

Drug Design, Development and Therapy 2008, 2:123-130

Published Date: 11 August 2008